These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9488206)

  • 1. Björn Folkow Award Lecture. The sympathetic nervous system in hypertension.
    Mancia G
    J Hypertens; 1997 Dec; 15(12 Pt 2):1553-65. PubMed ID: 9488206
    [No Abstract]   [Full Text] [Related]  

  • 2. Sympathetic activity, blood pressure variability and end organ damage in hypertension.
    Mancia G; Di Rienzo M; Parati G; Grassi G
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S3-8. PubMed ID: 9321734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive treatment and sympathetic excitation.
    Malliani A; Montano N
    Hypertension; 2005 Sep; 46(3):e8; author reply e8. PubMed ID: 16123377
    [No Abstract]   [Full Text] [Related]  

  • 4. The sympathetic nervous system in hypertension: differing effects of drug treatment.
    Sleight P
    Eur Heart J; 1998 Jun; 19 Suppl F():F39-44. PubMed ID: 9651734
    [No Abstract]   [Full Text] [Related]  

  • 5. [Increased activity of the sympathetic nervous system and the possibilities for therapeutic influence].
    Soucek M; Nevrlka J; Rihácek I; Frána P; Plachý M
    Vnitr Lek; 2007 May; 53(5):554-9. PubMed ID: 17642445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sympathetic neural activity in hypertension and related diseases.
    Grassi G
    Am J Hypertens; 2010 Oct; 23(10):1052-60. PubMed ID: 20651696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Point: Chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension.
    Esler M; Lambert E; Schlaich M
    J Appl Physiol (1985); 2010 Dec; 109(6):1996-8; discussion 2016. PubMed ID: 20185633
    [No Abstract]   [Full Text] [Related]  

  • 8. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Sympathetic nervous system, plasma volume, and hypertension.
    Christensen NJ
    J Appl Physiol (1985); 2010 Dec; 109(6):2003. PubMed ID: 21188813
    [No Abstract]   [Full Text] [Related]  

  • 9. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Activation of the sympathetic nervous system is the dominant contributor to systemic hypertension.
    Negrao CE; Negrao MV
    J Appl Physiol (1985); 2010 Dec; 109(6):2006. PubMed ID: 21188817
    [No Abstract]   [Full Text] [Related]  

  • 10. Sympathetic and baroreflex function in hypertension: implications for current and new drugs.
    Grassi G
    Curr Pharm Des; 2004; 10(29):3579-89. PubMed ID: 15579055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible role of the sympathetic nervous system in the pathogenesis of hypertension.
    Zanchetti A
    J Hypertens Suppl; 1985 Dec; 3(4):S57-9. PubMed ID: 3868712
    [No Abstract]   [Full Text] [Related]  

  • 12. [Imidazoline receptor agonists: are they actual today?].
    Nebieridze DV; Kamyshova TV
    Kardiologiia; 2012; 52(12):90-3. PubMed ID: 23237448
    [No Abstract]   [Full Text] [Related]  

  • 13. [How to treat effectively hypertensive patient with overactivity of sympathetic system?].
    Wańkowicz Z
    Pol Arch Med Wewn; 2002 Apr; 107(4):349-59. PubMed ID: 12189927
    [No Abstract]   [Full Text] [Related]  

  • 14. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Systemic hypertension--involvement of the CNS to this complex puzzle.
    Moreira TS; Takakura AC; Antunes VR
    J Appl Physiol (1985); 2010 Dec; 109(6):2004. PubMed ID: 21188814
    [No Abstract]   [Full Text] [Related]  

  • 15. Rebuttal from Esler, Lambert, and Schlaich.
    Esler M; Lambert E; Schlaich M
    J Appl Physiol (1985); 2010 Dec; 109(6):2000-1. PubMed ID: 21148350
    [No Abstract]   [Full Text] [Related]  

  • 16. [Sympathetic nervous factors, pressure variability and organ damage in arterial hypertension].
    Mancia G; Seravalle G; Grassi G
    Ann Ital Med Int; 1997; 12(4):217-22. PubMed ID: 9773576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High blood pressure management: potential benefits of I1 agents.
    Esler M
    J Hypertens Suppl; 1998 Aug; 16(3):S19-24. PubMed ID: 9747906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Dominant contributors for systemic hypertension--who leads, who follows?
    Braga VA
    J Appl Physiol (1985); 2010 Dec; 109(6):2007-8. PubMed ID: 21188840
    [No Abstract]   [Full Text] [Related]  

  • 19. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system.
    Rohrwasser A
    J Appl Physiol (1985); 2010 Dec; 109(6):2007. PubMed ID: 21188818
    [No Abstract]   [Full Text] [Related]  

  • 20. Antihypertensive drugs and the sympathetic nervous system.
    Del Colle S; Morello F; Rabbia F; Milan A; Naso D; Puglisi E; Mulatero P; Veglio F
    J Cardiovasc Pharmacol; 2007 Nov; 50(5):487-96. PubMed ID: 18030057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.